Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 17, 2009, summarizing the company's full-year results for 2008. The report introduces a new strategic framework focused on growing a diversified global business, delivering more products of value, and simplifying the operating model. GSK has shifted to dynamic web-based reporting for detailed information, with this document serving as a high-level summary.
Key Financial Metrics
| Metric | 2008 Value | 2007 Value |
|---|---|---|
| Turnover | £24.4 billion | £22.7 billion |
| Operating Profit (Total) | £7.1 billion | £7.6 billion |
| Profit After Tax (Total) | £4.7 billion | £5.3 billion |
| Profit Attributable to Shareholders | £4.6 billion | £5.2 billion |
| Earnings Per Share (EPS) | 88.6p | 94.4p |
| Free Cash Flow | £4.7 billion | Filing text does not provide a clear value |
| Dividend Per Share | 57p | 53p |
| Cash and Bank Overdrafts (End of Year) | £5.5 billion | £3.2 billion |
Material Changes Versus Prior Period
- Revenue: Total Group turnover decreased by 3% at constant exchange rates (CER) but increased by 7% in sterling terms due to currency fluctuations. Pharmaceutical turnover fell 3% CER, while Consumer Healthcare rose 3% CER.
- Profitability: EPS before major restructuring was 104.7p, down 9% CER. Total EPS declined to 88.6p from 94.4p in 2007, impacted by a £1.1 billion major restructuring charge.
- Segment Performance: Emerging Markets sales grew 12% CER to £2.3 billion, and Vaccines sales increased 15% CER to £2.5 billion. Core pharmaceuticals (excluding genericized products, Avandia, and pre-pandemic preparations) grew 10% to £16.4 billion.
- Balance Sheet: Total assets increased from £31.0 billion to £39.4 billion, while total equity decreased from £9.9 billion to £8.3 billion, largely due to restructuring costs and minority interest adjustments.
Guidance, Outlook, and Risks
Strategic Priorities: Management outlined three core priorities: diversifying the global portfolio (focusing on emerging markets and Japan), strengthening the R&D pipeline (12 products launched in 2008), and simplifying operations to reduce costs.
Restructuring: A restructuring program was expanded to deliver annual savings of £1.7 billion by 2011. In 2008, the company delivered over £500 million in cash flow benefits from working capital reduction.
Risks and Contingencies: The filing includes a "safe harbor" caution regarding forward-looking statements. Risks include the impact of exchange rates, patent expirations (genericization), and the execution of the restructuring plan. The company notes that actual results may differ materially from projections due to these uncertainties.
Investor Verification Checklist
- Verify the impact of the £1.1 billion major restructuring charge on 2008 operating profit and future cost savings targets.
- Confirm the specific contribution of Avandia and pre-pandemic preparations to the reported decline in pharmaceutical turnover.
- Review the full Annual Report for detailed breakdowns of the £4.7 billion free cash flow and the composition of the £21 billion non-current liabilities.
- Assess the progress of the 12 new product launches (e.g., Tyverb, Volibris) and their contribution to future revenue streams.
- Monitor the execution of the working capital reduction program and its sustained impact on liquidity.